Muscle Mass Difference among Patients With Chronic Kidney Disease Stage 3 to Stage 5

Ivena Ivena, Rudi Supriyadi, Setiawan Setiawan

Abstract


Background: Low muscle mass is one of the complications of chronic kidney disease (CKD), that may occur due to the accumulation of uremic toxins and other mechanisms related to CKD. The aim of this study was to explore the difference of muscle mass among CKD patients stage 3 to stage 5.

Methods: A cross-sectional study was conducted with comparative analysis, using secondary data collected during the year 2017 by total sampling method. Subjects were patients aged over 18 years with CKD stage 3 to stage 5 from three hospitals in Bandung. Chronic Kidney Disease stages were determined based on Glomerular Filtration Rate. Muscle mass data was determined using Bioelectrical Impedance Analysis, collected from previous research. Data were analyzed usingone-way ANOVA or Kruskal-Wallis test.

Results: One hundred subjects consisting of 57 men and 43 women were included in in this study with the mean muscle mass was 26.29%±4.86, of whom 67% of the patients had low muscle mass. There was no difference between male (27.21%±3.82) and female (28.36%±4.67). The muscle mass among patients withCKD stage 3 to stage 5 showed no significant results (p>0.05).

Conclusions: There is no difference in muscle mass among CKD stage 3 to stage 5.


Keywords


Chronic kidney disease, glomerular filtration rate, muscle mass

Full Text:

PDF

References


Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - A systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.

World Kidney Day. Chronic kidney disease. 2018. [cited 2018 August 5]. Available from: http://www.worldkidneyday.org/faqs/chronic-kidney-disease/.

GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.

Kementrian Kesehatan Republik Indonesi. Pusat data dan informasi kementrian kesehatan republik indonesia: situasi penyakit ginjal kronis. Jakarta: Kementrian Kesehatan Republik Indonesia; 2017.

Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s principles of internal medicine. 19th Ed. New York: McGraw Hill Education; 2015.

Wang XH, Mitch WE. Muscle wasting from kidney failure-a model for catabolic conditions. Int J Biochem Cell Biol. 2013;45(10):2230–8.

Wang DT, Yang YJ, Huang RH, Zhang ZH, Lin X. Myostatin activates the ubiquitin-proteasome and autophagy-lysosome systems contributing to muscle wasting in chronic kidney disease. Oxid Med Cell Longev. 2015;2015:684965.

Stenvinkel P, Carrero JJ, von Walden F, Ikizler TA, Nader GA. Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. Nephrol Dial Transplant. 2016;31(7):1070–7.

Oliveira EA, Cheung WW, Toma KG, Mak RH. Muscle wasting in chronic kidney disease. Pediatr Nephrol. 2018;33(5):789–98.

Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–70.

Olivier J. Wouters, Donal J. O’Donoghue, James Ritchie, Panos G. Kanavos, Narva AS. Early chronic kidney disease: diagnosis, management and models of care. Nat Rev Nephrol. 2015;11(8):491–502.

OMRON HealthCare. Instruction manual: body composition monitor HBF-375. Kyoto, Japan: OMRON Healthcare Co.,Ltd; 2012.

Prakash S, O’Hare AM. Interaction of aging and chronic kidney disease. Semin Nephrol. 2009;29(5):497–503.

McCance KL, Huether SE. Pathophysiology: the biologic basis for disease in adults and children. 7th ed. St. Louis, Missouri: Elsevier; 2013.

Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014;10(9):504–16.

Rajan VR, Mitch WE. Muscle wasting in chronic kidney disease: the role of the ubiquitin proteasome system and its clinical impact. Pediatr Nephrol. 2008;23(4):527–35.

Mitch WE, Remuzzi G. Diets for patients with chronic kidney disease, should we reconsider? BMC Nephrol. 2016;17(1):80.

Milam RH. Exercise guidelines for chronic kidney disease patients. J Ren Nutr. 2016;26(4):e23–5.




DOI: https://doi.org/10.15850/amj.v6n1.1505



 This Journal indexed by:

     

 

Creative Commons License
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats